MosaiQ®
MOSAIQ AiPlex CTD ASSAY – Accelerating Autoimmune diagnosis
Introducing our first IVDR CE-marked Microarray solution, MosaiQ AiPlex CTD, designed for laboratories to aid clinicians in the diagnosis of Connective Tissue Diseases on our fully automated, high-throughput platform, the MosaiQ system.
It can take up to 4 years to diagnose Autoimmune diseases*
Diagnosing Connective Tissue Diseases (CTD), such as Lupus, can be a painfully long and uncertain process. Because symptoms vary and are hard to differentiate, a blood test can help to identify CTD – sometimes even before symptoms become clear. The test helps physicians to rule out or confirm diagnosis by detecting autoantibodies associated with different Autoimmune diseases in the blood.
A comprehensive Autoimmune diagnostic solution
Our menu covers the eleven most clinically relevant CTD autoantibodies in one panel, providing laboratories and clinicians with more insights in one test and accelerating the time-to-results for the CTD diagnostic pathway.
The MosaiQ AiPlex CTD assay is designed for the simultaneous, qualitative detection of autoantibodies directed to double-stranded DNA and to the Extractable Nuclear Antigens TRIM21 (SS-A52, Ro-52), SS-A 60 (Ro-60), SS-B (La), Sm, Sm/RNP, U1RNP, Scl-70, Jo-1, CENP B, Ribosomal P Protein in human serum.
*Not available in all territories. Subject to regulatory clearance.
Your CTD panel with multiple analytes is superior to what the competitors can offer
European hospital laboratory
AiPlex CTD for the MosaiQ platform is designed to help reduce time-to-diagnosis for patients with CTD
Simple Workflow
Fast Results
Actionable Insights
The MosaiQ AiPlex CTD assay empowers laboratories and delivers diagnostic confidence to clinicians
